		6	43			
ė.			3006	<u></u>		
IDS Form PTO/SI	B/08: Substitute for for	m 1449A/P(O	bb I s	E C	omplete if Known	
		13		Application Number	10/533,924	
INFO	DRMATION D	uscLosď	RETRADE	Filing Date	November 21, 2005	
INFORMATION DISCLOSUREMAND STATEMENT BY APPLICANT				First Named Inventor	Ali AMARA	
317	ILIVILIAI DI	Ar I LIOA	1141	Art Unit	1614	
	(Use as many sheets	as necessary)		Examiner Name	Unknown	
Sheet	1	of	2	Attorney Docket Number	03495.0337	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS							
Examiner Initials	Cite No.1	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-4,522,811	06-11-1985	Eppstein et al.			
		US-4,683,195	07-28-1987	Mullis et al.			
· -		US-4,683,202	07-28-1987	Mullis			
		US-5,223,409	06-29-1993	Ladner et al.			
		US-5,403,484	04-04-1995	Ladner et al.			
		US-5,498,538	03-12-1996	Kay et al.	-		
		US-5,516,637	05-14-1996	Huang et al.			
		US-5,571,698	11-05-1996	Ladner et al.			
		US-5,625,033	04-29-1997	Kay et al.			
		US-5,658,727	08-19-1997	Barbas et al.			
		US-5,667,988	09-16-1997	Barbas et al.			
		US-6,391,567 B1	05-21-2002	Littman et al.			
		US-5,565,332 A	10-15-1996	Hoogenboom et al.			
		US-20040141968 A1	07-22-2004	Amara et al.			
		US-20040197330 A1	10-07-2004	Amara et al.			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶		
		EP 1046651 A1	10/25/2000	Figdor et al.				
,		WO 91/05876 A1	05/02/1991	Gehrz et al.				
		WO 00/63251	10/26/2000	KATHOLIEKE UNIVERSITEIT NIJMEGEN		-		
		WO 93/01820	02/04/1993	BRISTOL-MYERS SQUIBB COMPANY				
		WO 02/080851 A2	10/17/2002	THE JOHNS HOPKINS UNIVERSITY				
		WO 01/64752 A2	07/09/2001	NEW YORK UNIVERSITY				

NON PATENT LITERATURE DOCUMENTS						
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Desrosiers, R., "Prospects for an AIDS Vaccine," Nature Medicine, 10(3):221-233 (2004)				
		Feinberg et al, "AIDS Vaccine Models: Challenging Challenge Viruses," <i>Nature Medicine</i> , 9(3):207-210 (2002).				
		Greene, W., "The Brightening Future of HIV Therapeutics," Nature Immunology, 4(9):867-871 (2004).				
		Halary et al.; 'HUMAN CYTOMEGALOVIRUS BINDING TO DC-SIGN IS REQUIRED FOR DENDRITIC				

4			OIPE	包		
IDS Form PTO/S	B/08: Substitute for for	m 1449A/PT	APR 1 2 2006	3	Co	omplete if Known
		13		A	plication Number	10/533,924
INF	ORMATION D	ISCLOS	RE	5/	ing Date	November 21, 2005
STA	ORMATION D ATEMENT BY	APPLICA	PADEMA	Fil	rst Named Inventor	Ali AMARA
317	(I FIATE IA I DI	AFFLICA	714	Ar	t Unit	1614
	(Use as many sheets	as necessary)		Ex	raminer Name	Unknown
Sheet	2	of	2	At	torney Docket Number	03495.0337

 NON PATENT LITERATURE DOCUMENTS	
CELL INFECTION AND TARGET CELL TRANS-INFECTION"; Immunity, Vol. 17, No. 5, pages 653-664, (2002)	
Kwon et al.; "DC-SIGN-MEDIATED INTERNALIZATION OF HIV IS REQUIRED FOR TRANS- ENHANCEMENT OF T CELL INFECTION"; Immunity, Vol. 16, No. 1, pages 135-144, (2002)	
MacDonald et al., "Mucosal and Parenteral Vaccination Against Acute and Latent MCMV," J. VIrology, 72(1):442-451 (1998).	
Navarro-Sanchez et al.; "DENDRITIC-CELL-SPECIFIC ICAM3-GRABBING NON-INTEGRIN IS ESSENTIAL FOR THE PRODUCTIVE INFECTION OF HUMAN DENDRITIC CELLS BY MOSQUITO-CELL-DERIVED DENGUE VIRUSES"; EMBO Reports, Vol. 4, No. 7, pages 723-728, (2003)	•
Tassaneetrithep et al.; "DC-SING (CD209) MEDIATES DENGUE VIRUS INFECTION OF HUMAN DENDRITIC CELLS"; Journal of Experimental Medicine, Vol. 197, No. 7, pages 823-829, (2003)	
Wang et al., "Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Gylcoprotein B, J. Virology, 78(8):3965-3976 (2004).	
Men et al., "Identification of Chimpanzee fab Fragments," Journal of Virology, 2004, 78(9): 4665-4674.	
Brandriss et al. "LETHAL 17D YELLOW FEVER ENCEPHALITIS IN MICE", Journal of General Virology, 1986, 67:229-234.	
Lyssen et al., "PERSPECTIVES FOR THE TREATMENT OF INFECTIONS WITH FLAVIVIRDAE, Clinical Microbiology Reviews, 2000, 13(1):67-82.	
Curtis, Benson M. et al., "SEQUENCE AND EXPRESSION OF A MEMBRANE-ASSOCIATED C-TYPE LECTIN THAT EXHIBITS CD4-INDEPENDENT BINDING OF HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN gp120," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 8356-8360 (1992).	;
Geijtenbeek, Teunis B.H. et al., "IDENTIFICATION OF DC-SIGN, A NOVEL DENDRITIC CELL-SPECIFIC ICAM-3 RECEPTOR THAT SUPPORTS PRIMARY IMMUNE RESPONSES," Cell, Vol. 100, pp. 575-585 (2000).	
Tailleux, Ludovic et al., "DC-SIGN IS THE MAJOR MYCOBACTERIUM TUBERCULOSIS RECEPTOR ON HUMAN DENDRITIC CELLS," The Journal of Experimental Medicine, Vol. 197, pp. 121-127 (2003).	
 Patent Application No. 10/464,531 of Oliver NEYROLLES, Oliver SCHWARTZ, Ludvic TAILLEUX, and Philippe LAGRANGE, filed June 19, 2003 (Identified by Attorney Docket No. 03495.0270).	
Copy of Office Action dated December 28, 2004, in Application No. 10/700,507 (identified by Attorney Docket No. 03495.0301).	
Copy of Office Action dated October 17, 2005, in Application No. 10/700,507 (identified by Attorney Docket No. 03495.0301).	
Copy of Office Action dated December 28, 2004, in Application No. 10/700,491 (identified by Attorney Docket No. 03495.0300).	
Copy of Office Action dated July 26, 2005, in Application No. 10/700,491 (identified by Attorney Docket No. 03495.0300).	

Examiner	Stony B. Chon/	Date	06/20/2008
Signature	/Stacy B. Chen/	Considered	06/20/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/